Survey on patient preferences for myeloma treatment - Myeloma

  Dutch (Nederlands)  Voorkeuren van patiënten omtrent behandelingen voor myeloom Finnish (suomi) Potilaan mieltymykset myelooman hoidoista French (français) Préférences des patients concernant les traitements du myélome German (Deutsch) Patientenpräferenzen zu Myelombehandlungen Romanian (Română) Preferințele pacientului cu privire la tratamentele pentru mielom Spanish (Español) Preferencias del paciente sobre los tratamientos del mieloma     Our work is driven by the needs of myeloma patients. To best represent the patient voice in policy decisions, we need to…

Cancers, Free Full-Text

Multiple myeloma - The Lancet

Trends in overall survival and costs of multiple myeloma, 2000–2014

DRd: MAIA Trial DARZALEX® (daratumumab) & DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj) HCP

Additional Trials DARZALEX® (daratumumab) & DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj) HCP

Prognostic and predictive biomarker developments in multiple myeloma, Journal of Hematology & Oncology

PDF) Decision Aids: Assisting Patients With Multiple Myeloma and Caregivers With Treatment Decision Making

EasyM - A personalized MS-based assay to monitor multiple 2 myeloma disease assessment facilitated by the Evosep One - Evosep Biosystems

Triplet Therapy, Transplantation, and Maintenance until Progression in Myeloma

Physician treatment preferences for relapsed/refractory multiple myeloma: a discrete choice experiment

Top 5 Most-Read Multiple Myeloma News of 2022

Multiple Myeloma Clinical Trial